Cutting-edge science and research are critical to developing new tools to catalyze the end of tuberculosis (TB). The US government plays a vital role in advancing research and development (R&D) for TB, as it is the largest supporter of TB R&D globally. Yet years of flat US government funding for TB R&D have eroded the prospect of new tests, treatments, and a vaccine to combat the rising threat of drug-resistant TB. Urgent advocacy and action are needed to maintain and increase US government funding for TB R&D.
Join Treatment Action Group (TAG) for a 90-minute webinar on TB R&D funding. This webinar builds upon the impending release of TAG's annual Report on Tuberculosis Research Funding Trends to begin discussion on next steps for TB R&D funding advocacy into 2017. Panelists will discuss the importance of TB research and implications of stagnant funding, share insights into what to expect in the TB R&D pipeline, and strategize on what we can do as a community to push for change and the necessary political will under a new US presidential administration. A moderated community Q&A session will take place after the panel discussion.
- Richard Chaisson, Director, Johns Hopkins Center for Tuberculosis Research
- Mike Frick, Senior TB/HIV Project Officer, Treatment Action Group
- Christine Lubinski, Vice President for Global Health, Infectious Diseases Society of America (IDSA)
Moderator: Marcus Low, Spotlight Editor and former Head of Policy at Treatment Action Campaign (TAC)
When: Wednesday, November 16 at 10:00am ET || 9:00am CT || 8:00am MT || 7:00am PT
Webinar is free, however registration is required to participate.